DiaMedica Therapeutics Inc.
DMAC · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -0.31 | 0.15 | 0.34 |
| FCF Yield | -10.07% | -20.28% | -27.75% | -15.84% |
| EV / EBITDA | -8.89 | -4.58 | -2.68 | -5.35 |
| Quality | ||||
| ROIC | -65.06% | -41.35% | -43.35% | -30.99% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.90 | 0.97 | 0.84 | 0.90 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -17.86% | -61.77% | 5.56% | -32.95% |
| Safety | ||||
| Net Debt / EBITDA | 0.11 | 0.21 | 0.30 | 0.34 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.21 |
| Cash Conversion Cycle | -8,797.44 | -11,266.33 | -10,716.40 | -6,022.50 |